Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides

Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na+/K+-ATPase. Cardiac glycosides have been used for ma...

Full description

Bibliographic Details
Main Authors:	Calderón-Montaño, José Manuel, Burgos-Morón, Estefanía, Orta, Manuel Luis, Maldonado-Navas, Dolores, García-Domínguez, Irene, López-Lázaro, Miguel
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033509/

id	pubmed-4033509
recordtype	oai_dc
spelling	pubmed-40335092014-06-03 Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides Calderón-Montaño, José Manuel Burgos-Morón, Estefanía Orta, Manuel Luis Maldonado-Navas, Dolores García-Domínguez, Irene López-Lázaro, Miguel Review Article Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na+/K+-ATPase. Cardiac glycosides have been used for many years in the treatment of cardiac congestion and some types of cardiac arrhythmias. Recent data suggest that cardiac glycosides may also be useful in the treatment of cancer. These compounds typically inhibit cancer cell proliferation at nanomolar concentrations, and recent high-throughput screenings of drug libraries have therefore identified cardiac glycosides as potent inhibitors of cancer cell growth. Cardiac glycosides can also block tumor growth in rodent models, which further supports the idea that they have potential for cancer therapy. Evidence also suggests, however, that cardiac glycosides may not inhibit cancer cell proliferation selectively and the potent inhibition of tumor growth induced by cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact caused by their ability to selectively kill human cells versus rodent cells. This paper reviews such evidence and discusses experimental approaches that could be used to reveal the cancer therapeutic potential of cardiac glycosides in preclinical studies. Hindawi Publishing Corporation 2014 2014-05-08 /pmc/articles/PMC4033509/ /pubmed/24895612 http://dx.doi.org/10.1155/2014/794930 Text en Copyright © 2014 José Manuel Calderón-Montaño et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Calderón-Montaño, José Manuel Burgos-Morón, Estefanía Orta, Manuel Luis Maldonado-Navas, Dolores García-Domínguez, Irene López-Lázaro, Miguel
spellingShingle	Calderón-Montaño, José Manuel Burgos-Morón, Estefanía Orta, Manuel Luis Maldonado-Navas, Dolores García-Domínguez, Irene López-Lázaro, Miguel Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
author_facet	Calderón-Montaño, José Manuel Burgos-Morón, Estefanía Orta, Manuel Luis Maldonado-Navas, Dolores García-Domínguez, Irene López-Lázaro, Miguel
author_sort	Calderón-Montaño, José Manuel
title	Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
title_short	Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
title_full	Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
title_fullStr	Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
title_full_unstemmed	Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides
title_sort	evaluating the cancer therapeutic potential of cardiac glycosides
description	Cardiac glycosides, also known as cardiotonic steroids, are a group of natural products that share a steroid-like structure with an unsaturated lactone ring and the ability to induce cardiotonic effects mediated by a selective inhibition of the Na+/K+-ATPase. Cardiac glycosides have been used for many years in the treatment of cardiac congestion and some types of cardiac arrhythmias. Recent data suggest that cardiac glycosides may also be useful in the treatment of cancer. These compounds typically inhibit cancer cell proliferation at nanomolar concentrations, and recent high-throughput screenings of drug libraries have therefore identified cardiac glycosides as potent inhibitors of cancer cell growth. Cardiac glycosides can also block tumor growth in rodent models, which further supports the idea that they have potential for cancer therapy. Evidence also suggests, however, that cardiac glycosides may not inhibit cancer cell proliferation selectively and the potent inhibition of tumor growth induced by cardiac glycosides in mice xenografted with human cancer cells is probably an experimental artifact caused by their ability to selectively kill human cells versus rodent cells. This paper reviews such evidence and discusses experimental approaches that could be used to reveal the cancer therapeutic potential of cardiac glycosides in preclinical studies.
publisher	Hindawi Publishing Corporation
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033509/
_version_	1612093222946865152

Evaluating the Cancer Therapeutic Potential of Cardiac Glycosides

Similar Items